↑ 疾患リストへ ← 戻る

 168. エーラス・ダンロス症候群 [臨床試験数:7,薬物数:14(DrugBank:10),標的遺伝子数:17,標的パスウェイ数:53] 

Searched query = "Ehlers-Danlos syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04036305July 26, 20192 September 2019Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy VolunteersLocal Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy VolunteersEhlers-Danlos Syndrome;Anesthesia, LocalDrug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2%;Drug: Bupivacaine Injection 0.5%Vanderbilt University Medical CenterUniversity of CalgaryRecruiting18 YearsN/AAll230Phase 3United States
2NCT02597361January 201623 July 2018Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.Ehlers-Danlos Syndrome, Vascular TypeDrug: Irbesartan;Drug: PlaceboAssistance Publique - Hôpitaux de ParisMinistry of Health, FranceRecruiting18 Years70 YearsAll108Phase 3France
3EUCTR2015-001065-76-FR28/09/201518 January 2016N/AN/A - ARCADEMedDRA version: 18.0 Level: PT Classification code 10014316 Term: Ehlers-Danlos syndrome System Organ Class: 10010331 - Congenital, familial and genetic disordersTrade Name: IRBESARTAN
Product Name: IRBESARTAN
Pharmaceutical Form: Coated tablet
INN or Proposed INN: irbesartan
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)AuthorisedFemale: yes
Male: yes
France
4NCT01446783September 201119 February 2015IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos PatientsIGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos PatientsEhlers-Danlos Syndrome, ClassicDrug: mecasermin;Drug: SalineBispebjerg HospitalNot recruiting18 YearsN/ABoth15N/ADenmark
5NCT01307527November 200819 February 2015Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VIBrittle Cornea Syndrome;Ehlers-Danlos Syndrome Type 6Drug: Riboflavin;Device: Kera-XHadassah Medical OrganizationRecruiting18 YearsN/ABoth1N/AIsrael
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00190411October 200319 February 2015Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular TypePrevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos SyndromeEHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT;CHROMOSOME 2q31.2 DELETION SYNDROMEDrug: celiprolol;Drug: ControlAssistance Publique - Hôpitaux de ParisAventis PharmaceuticalsNot recruiting15 Years65 YearsBoth54Phase 4France
7NCT00001966January 200019 February 2015Mind-Body Therapy for Pain in Ehlers-Danlos SyndromeA Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos SyndromeEhlers-Danlos Syndrome;PainDrug: Mind-body therapyNational Human Genome Research Institute (NHGRI)Not recruitingN/AN/ABoth40Phase 2United States

先頭へ